JP2017530187A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530187A5 JP2017530187A5 JP2017530389A JP2017530389A JP2017530187A5 JP 2017530187 A5 JP2017530187 A5 JP 2017530187A5 JP 2017530389 A JP2017530389 A JP 2017530389A JP 2017530389 A JP2017530389 A JP 2017530389A JP 2017530187 A5 JP2017530187 A5 JP 2017530187A5
- Authority
- JP
- Japan
- Prior art keywords
- imidazo
- amino
- quinolin
- alkyl
- ethoxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000003342 alkenyl group Chemical group 0.000 claims 17
- -1 - NH 2 Chemical group 0.000 claims 16
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 125000003277 amino group Chemical group 0.000 claims 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 6
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- YZOQZEXYFLXNKA-UHFFFAOYSA-N n-[4-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CC)=N3)CCCCNS(C)(=O)=O)C3=C(N)N=C21 YZOQZEXYFLXNKA-UHFFFAOYSA-N 0.000 claims 5
- 229960003301 nivolumab Drugs 0.000 claims 5
- 229960002621 pembrolizumab Drugs 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- QNOAFXQYZVGWMO-UHFFFAOYSA-N 1-[1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]-3-propylurea Chemical compound NC1=NC=2C=CC=CC2C2=C1N=C(N2CC(C)(C)NC(=O)NCCC)COCC QNOAFXQYZVGWMO-UHFFFAOYSA-N 0.000 claims 4
- RABCHZGIHKCQEP-UHFFFAOYSA-N 1-[2-[2-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-3-cyclohexylurea Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCNC(=O)NC1CCCCC1 RABCHZGIHKCQEP-UHFFFAOYSA-N 0.000 claims 4
- RKHPJMXDRRZPGD-UHFFFAOYSA-N 1-[4-(4-amino-2-butylimidazo[4,5-c][1,5]naphthyridin-1-yl)butyl]-3-butylurea Chemical compound C1=CC=NC2=C3N(CCCCNC(=O)NCCCC)C(CCCC)=NC3=C(N)N=C21 RKHPJMXDRRZPGD-UHFFFAOYSA-N 0.000 claims 4
- FHJATBIERQTCTN-UHFFFAOYSA-N 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC=CC2=C(N(C(CNCC)=N3)CC(C)(C)O)C3=C(N)N=C21 FHJATBIERQTCTN-UHFFFAOYSA-N 0.000 claims 4
- NXRIDAMREUIFDQ-UHFFFAOYSA-N 1-[4-amino-7-[5-(hydroxymethyl)pyridin-3-yl]-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC2=C3N(CC(C)(C)O)C(CCOC)=NC3=C(N)N=C2C=C1C1=CN=CC(CO)=C1 NXRIDAMREUIFDQ-UHFFFAOYSA-N 0.000 claims 4
- NFYMGJSUKCDVJR-UHFFFAOYSA-N 2-propyl-[1,3]thiazolo[4,5-c]quinolin-4-amine Chemical group C1=CC=CC2=C(SC(CCC)=N3)C3=C(N)N=C21 NFYMGJSUKCDVJR-UHFFFAOYSA-N 0.000 claims 4
- HCLMCYDABWTVKQ-UHFFFAOYSA-N 3-[4-amino-2-(ethoxymethyl)-7-pyridin-3-ylimidazo[4,5-c]quinolin-1-yl]propane-1,2-diol Chemical compound C1=CC2=C3N(CC(O)CO)C(COCC)=NC3=C(N)N=C2C=C1C1=CC=CN=C1 HCLMCYDABWTVKQ-UHFFFAOYSA-N 0.000 claims 4
- FQYRLEXKXQRZDH-UHFFFAOYSA-N 4-aminoquinoline Chemical compound C1=CC=C2C(N)=CC=NC2=C1 FQYRLEXKXQRZDH-UHFFFAOYSA-N 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229950009791 durvalumab Drugs 0.000 claims 4
- OOHUVTQQUWSOPZ-UHFFFAOYSA-N n-[1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]-2-ethoxyacetamide Chemical compound C1=CC=CC2=C3N(CC(C)(C)NC(=O)COCC)C(COCC)=NC3=C(N)N=C21 OOHUVTQQUWSOPZ-UHFFFAOYSA-N 0.000 claims 4
- SBHDTQQLGBQXLR-UHFFFAOYSA-N n-[3-[4-amino-1-(2-hydroxy-2-methylpropyl)-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-7-yl]phenyl]methanesulfonamide Chemical compound C1=CC2=C3N(CC(C)(C)O)C(CCOC)=NC3=C(N)N=C2C=C1C1=CC=CC(NS(C)(=O)=O)=C1 SBHDTQQLGBQXLR-UHFFFAOYSA-N 0.000 claims 4
- FNGOMDSFESDBEW-UHFFFAOYSA-N 1-(4-amino-2-ethyl-7-pyridin-4-ylimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol Chemical compound C1=CC2=C3N(CC(C)(C)O)C(CC)=NC3=C(N)N=C2C=C1C1=CC=NC=C1 FNGOMDSFESDBEW-UHFFFAOYSA-N 0.000 claims 3
- ZLZKHTRPQRBTHF-UHFFFAOYSA-N 1-[2-[2-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-3-phenylurea Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCNC(=O)NC1=CC=CC=C1 ZLZKHTRPQRBTHF-UHFFFAOYSA-N 0.000 claims 3
- QHPGZBNQBMJYAG-UHFFFAOYSA-N 1-[4-amino-2-(ethoxymethyl)-7-pyridin-4-ylimidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC2=C3N(CC(C)(C)O)C(COCC)=NC3=C(N)N=C2C=C1C1=CC=NC=C1 QHPGZBNQBMJYAG-UHFFFAOYSA-N 0.000 claims 3
- HLPUJJZDRNYGNZ-UHFFFAOYSA-N 2-(ethoxymethyl)-1-n-propan-2-yl-6,7,8,9-tetrahydroimidazo[4,5-c]quinoline-1,4-diamine Chemical compound C1CCCC2=C(N(C(COCC)=N3)NC(C)C)C3=C(N)N=C21 HLPUJJZDRNYGNZ-UHFFFAOYSA-N 0.000 claims 3
- DXDGDCBZWVCDHG-UHFFFAOYSA-N 2-amino-n-[2-(4-amino-2-butylimidazo[4,5-c][1,5]naphthyridin-1-yl)ethyl]-4-methylpentanamide Chemical compound C1=CC=NC2=C(N(C(CCCC)=N3)CCNC(=O)C(N)CC(C)C)C3=C(N)N=C21 DXDGDCBZWVCDHG-UHFFFAOYSA-N 0.000 claims 3
- RFZSZPJGVHUALX-UHFFFAOYSA-N 2-butyl-1-(3-methylsulfonylpropyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCCS(C)(=O)=O)C3=C(N)N=C21 RFZSZPJGVHUALX-UHFFFAOYSA-N 0.000 claims 3
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229960002751 imiquimod Drugs 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical group C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 3
- 229950010550 resiquimod Drugs 0.000 claims 3
- SVBZCXQPNPURIX-UHFFFAOYSA-N 1-(2-amino-2-methylpropyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)N)C3=C(N)N=C21 SVBZCXQPNPURIX-UHFFFAOYSA-N 0.000 claims 2
- BIWKOBSVKIEQLD-UHFFFAOYSA-N 1-[1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]-3-cyclopentylurea Chemical compound NC1=NC=2C=CC=CC2C2=C1N=C(N2CC(C)(C)NC(=O)NC2CCCC2)COCC BIWKOBSVKIEQLD-UHFFFAOYSA-N 0.000 claims 2
- RLGNIXAVMDVPSM-UHFFFAOYSA-N 1-[4-(3,5-dichlorophenyl)sulfonylbutyl]-2-ethylimidazo[4,5-c]quinolin-4-amine Chemical compound CCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCCS(=O)(=O)C1=CC(Cl)=CC(Cl)=C1 RLGNIXAVMDVPSM-UHFFFAOYSA-N 0.000 claims 2
- GRGBJCMHYKWROJ-UHFFFAOYSA-N 1-[4-(4-amino-2-butylimidazo[4,5-c][1,5]naphthyridin-1-yl)butyl]-3-cyclohexylurea Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CCCCNC(=O)NC1CCCCC1 GRGBJCMHYKWROJ-UHFFFAOYSA-N 0.000 claims 2
- GTUCHIHDDSGYMP-UHFFFAOYSA-N 1-[4-amino-2-(ethoxymethyl)-7-pyridin-3-ylimidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC2=C3N(CC(C)(C)O)C(COCC)=NC3=C(N)N=C2C=C1C1=CC=CN=C1 GTUCHIHDDSGYMP-UHFFFAOYSA-N 0.000 claims 2
- DITHACKITKTCMN-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[2-(3-phenylmethoxypropoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCCOCC1=CC=CC=C1 DITHACKITKTCMN-UHFFFAOYSA-N 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- WPCIWMJWVMQOBT-UHFFFAOYSA-N 4-[4-amino-2-(ethoxymethyl)-1-(2-hydroxy-2-methylpropyl)imidazo[4,5-c]quinolin-7-yl]-n-methoxy-n-methylbenzamide Chemical compound C1=CC2=C3N(CC(C)(C)O)C(COCC)=NC3=C(N)N=C2C=C1C1=CC=C(C(=O)N(C)OC)C=C1 WPCIWMJWVMQOBT-UHFFFAOYSA-N 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- LJCJRRKKAKAKRV-UHFFFAOYSA-N (2-amino-2-methylpropyl) 3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoate Chemical group CC(C)(N)COC(=O)CCC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 LJCJRRKKAKAKRV-UHFFFAOYSA-N 0.000 claims 1
- BXYZFBZFOPCYGD-UHFFFAOYSA-N 3-[[3-[3-benzoyl-8-(trifluoromethyl)quinolin-4-yl]phenoxy]methyl]benzoic acid Chemical compound OC(=O)C1=CC=CC(COC=2C=C(C=CC=2)C=2C3=CC=CC(=C3N=CC=2C(=O)C=2C=CC=CC=2)C(F)(F)F)=C1 BXYZFBZFOPCYGD-UHFFFAOYSA-N 0.000 claims 1
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 1
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 1
- 229940122255 Microtubule inhibitor Drugs 0.000 claims 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims 1
- UDHPLJGOINSMFG-UHFFFAOYSA-N [4-[4-amino-1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2-(ethoxymethyl)imidazo[4,5-c]quinolin-7-yl]phenyl]methanol Chemical compound CCOCC1=NC2=C(N)N=C3C=C(C=4C=CC(CO)=CC=4)C=CC3=C2N1CC1COC(C)(C)O1 UDHPLJGOINSMFG-UHFFFAOYSA-N 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- WUESWDIHTKHGQA-UHFFFAOYSA-N cyclohexylurea Chemical compound NC(=O)NC1CCCCC1 WUESWDIHTKHGQA-UHFFFAOYSA-N 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 101150108262 gnrh1 gene Proteins 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 231100000782 microtubule inhibitor Toxicity 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- BQLBSBWCGKYXGM-UHFFFAOYSA-N n-[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)-2,2-dimethylpropyl]benzamide Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC(C)(C)CNC(=O)C1=CC=CC=C1 BQLBSBWCGKYXGM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 0 CC(CC(*1CC(C)(COC(C)(C)*)C=C)=O)C1=O Chemical compound CC(CC(*1CC(C)(COC(C)(C)*)C=C)=O)C1=O 0.000 description 3
- MEGLZQBTTRKCDK-UHFFFAOYSA-N Cc1ccc(CO[NH+](C)[IH-])cc1 Chemical compound Cc1ccc(CO[NH+](C)[IH-])cc1 MEGLZQBTTRKCDK-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410440824.0 | 2014-09-01 | ||
| CN201410440824.0A CN105440135A (zh) | 2014-09-01 | 2014-09-01 | 用于治疗肿瘤的抗-pd-l1结合物 |
| PCT/CN2015/088456 WO2016034085A1 (en) | 2014-09-01 | 2015-08-29 | Anti-pd-l1 conjugates for treating tumors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530187A JP2017530187A (ja) | 2017-10-12 |
| JP2017530187A5 true JP2017530187A5 (enExample) | 2018-10-04 |
| JP6921745B2 JP6921745B2 (ja) | 2021-08-18 |
Family
ID=55439131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530389A Expired - Fee Related JP6921745B2 (ja) | 2014-09-01 | 2015-08-29 | 腫瘍を治療するための抗ｐｄ−ｌ１コンジュゲート |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11130812B2 (enExample) |
| EP (3) | EP3763742B1 (enExample) |
| JP (1) | JP6921745B2 (enExample) |
| KR (1) | KR20170072192A (enExample) |
| CN (4) | CN105440135A (enExample) |
| AU (2) | AU2015311400B2 (enExample) |
| CA (1) | CA2959564A1 (enExample) |
| DK (1) | DK3189082T3 (enExample) |
| ES (1) | ES2822560T3 (enExample) |
| WO (1) | WO2016034085A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2376535T (pt) | 2008-12-09 | 2017-06-23 | Hoffmann La Roche | Anticorpos anti-pd-l1 e a sua utilização para a melhoria do funcionamento das células t |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| CA2936375A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating her2 positive tumors |
| MX2016012779A (es) | 2014-03-31 | 2017-04-27 | Genentech Inc | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. |
| CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| FI4001311T3 (fi) | 2014-07-09 | 2026-01-27 | Birdie Biopharmaceuticals Inc | Pd-l1/pd-1-vasta-aineiden yhdistelmiä kasvaimien hoitoon |
| EP3268392A2 (en) | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| PT3303396T (pt) | 2015-05-29 | 2023-01-30 | Bristol Myers Squibb Co | Anticorpos contra ox40 e utilizações dos mesmos |
| PH12017501857B1 (en) * | 2015-06-16 | 2024-01-17 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
| AU2016322813B2 (en) | 2015-09-14 | 2021-04-01 | Pfizer Inc. | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors |
| PE20240096A1 (es) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| WO2017106453A1 (en) | 2015-12-17 | 2017-06-22 | University Of Maryland, Baltimore County | A recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CA3021349A1 (en) | 2016-04-19 | 2017-10-26 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| WO2017184735A1 (en) | 2016-04-19 | 2017-10-26 | Ifm Therapeutics, Inc | Nlrp3 modulators |
| JP7043425B2 (ja) * | 2016-06-06 | 2022-03-29 | ジェネンテック， インコーポレイテッド | シルベストロール抗体－薬物コンジュゲート及び使用方法 |
| CN107574149B (zh) * | 2016-07-05 | 2022-02-18 | 上海细胞治疗研究院 | 一种树突状细胞的促成熟方法及其用途 |
| WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
| WO2018039332A1 (en) | 2016-08-23 | 2018-03-01 | The Johns Hopkins University | Immunoswitch nanoparticles for reprogrammed t cell responses |
| KR20190075921A (ko) | 2016-10-28 | 2019-07-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| TWI873080B (zh) * | 2017-05-12 | 2025-02-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | 含有ＴＧＦ-β受體的融合蛋白及其醫藥用途 |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| CN110769827A (zh) | 2017-06-23 | 2020-02-07 | 博笛生物科技有限公司 | 药物组合物 |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| MX2020009864A (es) * | 2018-03-23 | 2021-01-08 | Lilly Co Eli | Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1. |
| CA3094763C (en) | 2018-03-23 | 2024-01-02 | Eli Lilly And Company | Anti-cd137 antibodies for combination with anti-pd-l1 antibodies |
| CA3097865A1 (en) | 2018-04-25 | 2019-10-31 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| AU2019282150A1 (en) * | 2018-06-04 | 2020-10-29 | Avacta Life Sciences, Limited | Tumor microenvironment-activated drug-binder conjugates, and uses related thereto |
| KR102768379B1 (ko) | 2018-08-16 | 2025-02-13 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 이미다조[4,5-c]퀴놀린 유래 NLRP3-조정제 |
| US12024513B2 (en) | 2018-08-16 | 2024-07-02 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN109897036B (zh) * | 2019-03-15 | 2021-07-30 | 沈阳药科大学 | 三唑并吡啶类化合物及其制备方法和用途 |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| CN113122541A (zh) | 2019-12-31 | 2021-07-16 | 财团法人工业技术研究院 | 核酸药物复合体以及其用途 |
| US20230094832A1 (en) * | 2020-01-30 | 2023-03-30 | Research & Business Foundation Sungkyunkwan University | Antibody-drug conjugate comprising immune checkpoint inhibitor and exosome secretion inhibitor, and pharmaceutical composition comprising same |
| CN116056725A (zh) * | 2020-08-04 | 2023-05-02 | 蛋白科技先鋒 | 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途 |
| WO2022237884A1 (zh) * | 2021-05-13 | 2022-11-17 | 清华大学 | 一种抗体药物偶联物及其制备方法和应用 |
| WO2023039243A2 (en) * | 2021-09-13 | 2023-03-16 | Achelois Biopharma, Inc. | Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use |
| PE20250930A1 (es) * | 2022-08-03 | 2025-04-02 | Seagen Inc | Conjugados de farmacos anti-pd-l1 inmunoestimuladores |
| WO2024238588A2 (en) * | 2023-05-15 | 2024-11-21 | The Research Foundation For The State University Of New York | Targeted delivery of dual payload of mmaf or mmae and tlr7 agonists for the treatment of cancer |
| CN118286386A (zh) * | 2024-04-09 | 2024-07-05 | 复旦大学附属中山医院 | Nod1激动剂在制备治疗肝细胞癌药物中的用途 |
Family Cites Families (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US6399754B1 (en) | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5874218A (en) | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
| US6001577A (en) | 1998-06-08 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5853984A (en) | 1990-06-11 | 1998-12-29 | Nexstar Pharmaceuticals, Inc. | Use of nucleic acid ligands in flow cytometry |
| US6465189B1 (en) | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Systematic evolution of ligands by exponential enrichment: blended selex |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US6280932B1 (en) | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
| US5789163A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Enzyme linked oligonucleotide assays (ELONAS) |
| US6716580B2 (en) | 1990-06-11 | 2004-04-06 | Somalogic, Inc. | Method for the automated generation of nucleic acid ligands |
| US5475096A (en) | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| US5226575A (en) | 1991-11-21 | 1993-07-13 | Scott Faust | Pneumatic mortar dispenser with flex release |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US6458539B1 (en) | 1993-09-17 | 2002-10-01 | Somalogic, Inc. | Photoselection of nucleic acid ligands |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5843732A (en) | 1995-06-06 | 1998-12-01 | Nexstar Pharmaceuticals, Inc. | Method and apparatus for determining consensus secondary structures for nucleic acid sequences |
| JP2000503639A (ja) | 1995-12-22 | 2000-03-28 | ブリストル―マイヤーズ スクイブ カンパニー | 分枝ヒドラゾンのリンカー類 |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| ATE228529T1 (de) | 1996-08-30 | 2002-12-15 | Jens Peter Fuerste | Spiegelselektion und spiegelevolution von nucleinsäuren |
| US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
| UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| US6403779B1 (en) | 1999-01-08 | 2002-06-11 | Isis Pharmaceuticals, Inc. | Regioselective synthesis of 2′-O-modified nucleosides |
| US20030054360A1 (en) | 1999-01-19 | 2003-03-20 | Larry Gold | Method and apparatus for the automated generation of nucleic acid ligands |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| CN100482281C (zh) | 1999-06-25 | 2009-04-29 | 基因技术股份有限公司 | 抗ErbB抗体-类美坦素偶联物在制备药物中的应用 |
| US6506887B1 (en) | 1999-07-29 | 2003-01-14 | Somalogic, Incorporated | Conditional-selex |
| US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| AU784062B2 (en) | 1999-08-23 | 2006-01-19 | Dana-Farber Cancer Institute, Inc. | Novel B7-4 molecules and uses therefor |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
| US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| WO2006091720A2 (en) | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
| UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
| UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
| MXPA03008959A (es) | 2001-04-02 | 2004-10-15 | Wyeth Corp | Pd-1, un receptor para b7-4 y sus usos. |
| US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| ATE452655T1 (de) | 2001-06-10 | 2010-01-15 | Noxxon Pharma Ag | Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung |
| AU2775402A (en) | 2001-06-29 | 2003-01-02 | Medimolecular Pty Ltd | Nucleic acid ligands to complex targets |
| US20030139364A1 (en) | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| CA2466279A1 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| ATE416771T1 (de) | 2001-11-16 | 2008-12-15 | 3M Innovative Properties Co | N-ä4-(4-amino-2-ethyl-1h-imidazoä4,5-cüchinolin 1-yl)butylümethanesulfonamide, diese enthaltende pharmazeutische zusammensetzung und deren verwendung |
| HRP20040541A2 (en) | 2001-11-27 | 2004-10-31 | Anadys Pharmaceuticals | 3- -D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF |
| AU2002360733A1 (en) | 2001-12-31 | 2003-07-24 | Guilford Pharmaceuticals Inc. | SUBSTITUTED 4,9-DIHYDROCYCLOPENTA(imn)PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US20040092470A1 (en) | 2002-06-18 | 2004-05-13 | Leonard Sherry A. | Dry powder oligonucleotide formualtion, preparation and its uses |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CA2802205C (en) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| EP1413316A1 (en) | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US20050036951A1 (en) | 2003-01-09 | 2005-02-17 | Arizeke Pharmaceuticals, Inc. | Methods of treating lung diseases |
| US9259459B2 (en) | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物 |
| EP1594542B1 (en) | 2003-02-20 | 2010-06-30 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer |
| WO2005025583A2 (en) | 2003-09-05 | 2005-03-24 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
| CA2542099A1 (en) | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| ITMI20032121A1 (it) | 2003-11-04 | 2005-05-05 | Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm | Procedimento per la preparazione di imiquimod e suoi intermedi |
| CN103394083B (zh) * | 2003-11-06 | 2017-07-18 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| WO2005067500A2 (en) | 2003-12-30 | 2005-07-28 | 3M Innovative Properties Company | Enhancement of immune responses |
| EP1728793B1 (en) | 2004-03-26 | 2016-02-03 | Sumitomo Dainippon Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
| JP2008506683A (ja) | 2004-07-18 | 2008-03-06 | コーリー ファーマシューティカル グループ， リミテッド | 先天免疫応答を誘導するための方法および組成物 |
| SI1791565T1 (sl) * | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
| EP1809671B1 (en) | 2004-11-09 | 2014-07-16 | University Of Southern California | CpG/antibody conjugate against cancer |
| EP1830876B1 (en) | 2004-12-30 | 2015-04-08 | Meda AB | Use of imiquimod for the treatment of cutaneous metastases derived from a breast cancer tumor |
| EP1871418B1 (en) | 2005-04-19 | 2014-03-19 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
| CN101355928B (zh) | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
| CN104293780A (zh) | 2005-05-04 | 2015-01-21 | 诺松制药股份公司 | 结合hmga的核酸 |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| WO2007008848A2 (en) * | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| CN101309933A (zh) * | 2005-09-07 | 2008-11-19 | 米迪缪尼有限公司 | 毒素偶联的Eph受体抗体 |
| JP2009506790A (ja) * | 2005-09-07 | 2009-02-19 | メディミューン，エルエルシー | 毒素とコンジュゲートしたｅｐｈ受容体抗体 |
| WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
| WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
| EP2041135A4 (en) | 2006-07-05 | 2010-12-01 | Astrazeneca Ab | As TLR7 MODULATORS, 8-OXOADENINE DERIVATIVES WORK |
| CA2667019C (en) | 2006-10-27 | 2016-03-29 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| US20080149123A1 (en) * | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| EP2125007B9 (en) | 2007-02-07 | 2014-04-16 | The Regents of The University of California | Conjugates of synthetic tlr agonists and uses therefor |
| CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
| CA2695385A1 (en) | 2007-07-31 | 2009-02-05 | Atul Bedi | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| EA023175B1 (ru) | 2007-09-28 | 2016-05-31 | Бинд Терапьютикс, Инк. | Таргетирование раковых клеток с использованием наночастиц |
| US8062852B2 (en) | 2007-10-01 | 2011-11-22 | The Children's Hospital And Regional Medical Center | Detection and treatment of autoimmune disorders |
| EA018579B1 (ru) | 2008-01-15 | 2013-09-30 | Меда Аб | Способ лечения полипов/полипоза и предраковых изменений толстого кишечника |
| AU2009207287B2 (en) | 2008-01-25 | 2014-09-11 | Gavish-Galilee Bio Applications Ltd | Targeting of innate immune response to tumor site |
| CN102088974A (zh) | 2008-02-07 | 2011-06-08 | 加利福尼亚大学校务委员会 | 用tlr7活化剂对膀胱疾病的治疗 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| NZ621433A (en) | 2008-03-18 | 2015-10-30 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| MX2011006152A (es) | 2008-12-09 | 2011-07-28 | Gilead Sciences Inc | Moduladores de receptores tipo toll. |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| PT2427485T (pt) | 2009-05-07 | 2017-03-13 | Immunocellular Therapeutics Ltd | Epitopos cd133 |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| AR082686A1 (es) | 2010-08-13 | 2012-12-26 | Baylor Res Inst | Adyuvantes de vacuna que direccionan a los adyuvantes de anticuerpos directamente hacia las celulas presentadoras de antigenos |
| CA2818669A1 (en) | 2010-12-09 | 2012-06-14 | Barbara Klencke | Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1 |
| WO2012088635A1 (zh) * | 2010-12-30 | 2012-07-05 | 中国科学院自动化研究所 | 车辆自适应巡航控制系统及方法 |
| HUE032638T2 (en) | 2011-01-12 | 2017-10-30 | Ventirx Pharmaceuticals Inc | Toll receptor modulator substituted benzoazepines |
| AR085633A1 (es) | 2011-03-08 | 2013-10-16 | Baylor Res Inst | Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| AU2012244549B2 (en) | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| LT2734551T (lt) | 2011-07-24 | 2018-04-10 | Cure Tech Ltd. | Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai |
| JP6238459B2 (ja) * | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| JP6046716B2 (ja) | 2011-08-11 | 2016-12-21 | ハンツマン・アドバンスド・マテリアルズ・アメリカズ・エルエルシー | ベンゾオキサジン化合物の生産方法 |
| CA2849259A1 (en) * | 2011-09-19 | 2013-03-28 | The Johns Hopkins University | Cancer immunotherapy |
| US9241869B2 (en) | 2011-10-25 | 2016-01-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US10344261B2 (en) | 2011-11-09 | 2019-07-09 | Ascend Biopharmaceuticals Ltd | Immunomodulatory conjugates |
| CA2856895C (en) | 2011-11-28 | 2021-10-26 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
| WO2013166110A1 (en) | 2012-05-02 | 2013-11-07 | Yale University | Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms) |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| US9845356B2 (en) * | 2012-08-03 | 2017-12-19 | Dana-Farber Cancer Institute, Inc. | Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use |
| SG11201501286PA (en) * | 2012-08-23 | 2015-05-28 | Agensys Inc | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
| WO2014060112A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| US10000482B2 (en) | 2012-10-19 | 2018-06-19 | Origenis Gmbh | Kinase inhibitors |
| CA2936375A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating her2 positive tumors |
| FI4001311T3 (fi) | 2014-07-09 | 2026-01-27 | Birdie Biopharmaceuticals Inc | Pd-l1/pd-1-vasta-aineiden yhdistelmiä kasvaimien hoitoon |
| CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
| US10821127B2 (en) | 2015-11-09 | 2020-11-03 | Shaperon Inc. | Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CN110769827A (zh) | 2017-06-23 | 2020-02-07 | 博笛生物科技有限公司 | 药物组合物 |
| CN113164460A (zh) | 2018-09-07 | 2021-07-23 | 博笛生物科技有限公司 | 咪唑喹啉化合物及其应用 |
| EP3902532A4 (en) | 2018-12-26 | 2022-08-24 | Birdie Biopharmaceuticals, Inc. | Immune modulatory combinations and methods for treating cancers |
-
2014
- 2014-09-01 CN CN201410440824.0A patent/CN105440135A/zh active Pending
- 2014-09-01 CN CN202011360594.9A patent/CN112587672A/zh active Pending
- 2014-09-01 CN CN202011353067.5A patent/CN112546238A/zh active Pending
-
2015
- 2015-08-29 ES ES15839010T patent/ES2822560T3/es active Active
- 2015-08-29 DK DK15839010.4T patent/DK3189082T3/da active
- 2015-08-29 WO PCT/CN2015/088456 patent/WO2016034085A1/en not_active Ceased
- 2015-08-29 CN CN201580037746.2A patent/CN107074959A/zh active Pending
- 2015-08-29 CA CA2959564A patent/CA2959564A1/en active Pending
- 2015-08-29 US US15/508,033 patent/US11130812B2/en not_active Expired - Fee Related
- 2015-08-29 AU AU2015311400A patent/AU2015311400B2/en not_active Ceased
- 2015-08-29 KR KR1020177008631A patent/KR20170072192A/ko not_active Ceased
- 2015-08-29 JP JP2017530389A patent/JP6921745B2/ja not_active Expired - Fee Related
- 2015-08-29 EP EP20191420.7A patent/EP3763742B1/en active Active
- 2015-08-29 EP EP15839010.4A patent/EP3189082B1/en active Active
- 2015-08-29 EP EP22199269.6A patent/EP4148069A1/en not_active Withdrawn
-
2021
- 2021-02-23 AU AU2021201166A patent/AU2021201166A1/en not_active Abandoned
- 2021-08-18 US US17/405,680 patent/US20220033503A1/en not_active Abandoned